GenFleet Therapeutics announced the advancement of a phase Ib/II combination study of GFH276, an oral Pan RAS inhibitor, in a multicenter, open-label study at dozens of sites across China and Australia; the first overseas patient was recently dosed at Australia’s Monash Health, and the first Chinese patient was dosed at China’s Fudan University Cancer Hospital in the third quarter of this year. The study will assess the efficacy and safety of multiple combination regimens in patients with RAS-mutant pancreatic cancer and solid tumors. The phase II trial will include three regimens treating pancreatic cancers in the first-line setting; the combinations include GFH276 with cetuximab (EGFR antibody), GFH276 with AG (standard-of-care chemotherapy), and GFH276 with mFOLFIRINOX (standard-of-care chemotherapy).
The first patient was dosed in the clinical trial of GFH276 monotherapy for pretreated solid tumors in September 2025, advancing with first-tier progress in China’s Pan RAS inhibitor development. According to the late-breaking abstract (LBA) at the ESMO annual meeting this year, 72.6% of pancreatic ductal adenocarcinoma (PDAC) patients received GFH276 as the third- or later-line therapy in phase Ia monotherapy trial as of data cutoff date; no dose-limiting toxicities were observed across 40-160 mg QD dose levels when patients did not receive prophylactic medications; the overall objective response rate (ORR) was 41.1% among 61 efficacy-evaluable PDAC patients (40-160 mg QD), and 43.1% among RAS inhibitor naive patients. According to the poster presentation at this year’s AACR annual meeting, animal models across tumor types indicated notable synergistic effects in combination of GFH276 with standard-of-care regimens including EGFR antibody and chemotherapy, along with superior ani tumor efficacy; the preclinical results offered evidence in translational medicine for this clinical study.
“Monotherapy and chemotherapy-combination studies evaluating Pan RAS inhibitors in solid tumors including pancreatic cancer, have demonstrated the potential of novel targeted approaches to transform survival outcome in major oncology indications. With track record in clinical development of globally competitive first-line combination trials comprising KRAS G12C/G12D inhibitors, GenFleet is well-positioned to leverage deep expertise in developing RAS-targeted therapeutics to deliver most appropriate therapeutic regimens for patients harboring various RAS mutations and advance more innovative treatments into the first-line setting.”stated Yu Wang, M.D., Ph.D., Chief Medical Officer of GenFleet.
According to Frost & Sullivan data, RAS mutations occur in approximately 30% of global cancer patients, with an estimated annual incidence of over 6 million new cases harboring RAS mutations from 2025 to 2032; among them, nearly 90% of pancreatic cancer patients harbor RAS mutations. With multiple RAS inhibitors now approved in China and globally, alongside an abundance of multi-modality investigational Pan RAS inhibitors advancing into mid- or late-stage trials, the immense market potential and growth chances for these therapies are increasingly apparent. DelveInsight projects a 35% CAGR for KRAS (largest RAS mutation subtype) inhibitors over the next decade, while peak-sales estimate for Pan RAS inhibitors has climbed sharply from $230 million (GlobalData, late 2024) to $8.3 billion (Bloomberg, 2026).
About RAS Proteins and GFH276
RAS proteins, in active GTP-bound or inactive GDP-bound form, are binary molecular switches controlling cellular responses in signaling pathways including RAF-MEK-ERK and PI3K-AKT mTOR. Three RAS genes encode for protein isoforms, namely Kirsten Ras (KRAS), Harvey Ras (HRAS) and Neuroblastoma Ras (NRAS), and KRAS is the most frequent RAS mutation in humans.
GFH276 is an oral novel small-molecule Pan RAS (ON) inhibitor employing the tri-complex mechanism (Cyp A-GFH276-RAS) to target active RAS proteins of most wild/mutant subtypes, including most commonly found KRAS mutant (G12C, G12D, G12V, etc.) proteins, as well as NRAS and HRAS isoforms. Preclinical research of GFH276 demonstrates dose-dependent anti-tumor activity and drives tumor regression in multiple KRAS mutant tumor models. GFH276 also holds the potential to outperform SIIP (switch II pocket)-based KRAS inhibitors in overcoming adaptive and acquired resistance.
Forward-looking Statements
Specific information in this press release may contain or constitute forward-looking words that are not historical facts. They can be identified by using forward-looking terminology, such as "predict", "believe", "plan", "predict", "expect", "will", "may", "should" and other words of similar meanings.Based on the management's current beliefs, plans, estimates and expectations of the company's operation and market trends subject to changes beyond control, the forward-looking terminology reflects GenFleet Therapeutics' beliefs, plans, estimates and expectations of future development. Actual outcome in the future may differ significantly from forward-looking words owing to market, policy, and R&D uncertainties, among others.Subject to the above-mentioned uncertainties, GenFleet Therapeutics makes no expressed or implied guarantee as to the accuracy, completeness or feasibility of this presentation, and you are cautioned not to solely rely on such forward-looking words.Neither the company nor any of its directors, officers, employees, shareholders, agents, related parties, consultants or representatives will be liable to you or any other person for consequences resulting from using this presentation. Investors are advised to exercise due diligence with reference to the company's official disclosures for decision-making.